JP2009511632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511632A5 JP2009511632A5 JP2008536724A JP2008536724A JP2009511632A5 JP 2009511632 A5 JP2009511632 A5 JP 2009511632A5 JP 2008536724 A JP2008536724 A JP 2008536724A JP 2008536724 A JP2008536724 A JP 2008536724A JP 2009511632 A5 JP2009511632 A5 JP 2009511632A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- retinal
- disease
- kit
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 35
- 229920000642 polymer Polymers 0.000 claims 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 6
- 230000002207 retinal Effects 0.000 claims 6
- 235000020945 retinal Nutrition 0.000 claims 6
- 239000011604 retinal Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 5
- 208000002780 Macular Degeneration Diseases 0.000 claims 4
- 229920000954 Polyglycolide Polymers 0.000 claims 4
- 208000004644 Retinal Vein Occlusion Diseases 0.000 claims 4
- 230000001154 acute Effects 0.000 claims 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 4
- 239000004633 polyglycolic acid Substances 0.000 claims 4
- 201000011056 retinal disease Diseases 0.000 claims 4
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 3
- 208000002691 Choroiditis Diseases 0.000 claims 3
- 208000005721 HIV Infections Diseases 0.000 claims 3
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 3
- 208000002367 Retinal Perforations Diseases 0.000 claims 3
- 210000003583 Retinal Pigment Epithelium Anatomy 0.000 claims 3
- 206010038848 Retinal detachment Diseases 0.000 claims 3
- 208000007014 Retinitis Pigmentosa Diseases 0.000 claims 3
- 206010038932 Retinopathy Diseases 0.000 claims 3
- 206010038923 Retinopathy Diseases 0.000 claims 3
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 239000004621 biodegradable polymer Substances 0.000 claims 3
- 229920002988 biodegradable polymer Polymers 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 230000004264 retinal detachment Effects 0.000 claims 3
- 230000001225 therapeutic Effects 0.000 claims 3
- 210000001772 Blood Platelets Anatomy 0.000 claims 2
- 210000001736 Capillaries Anatomy 0.000 claims 2
- 206010061744 Carotid artery disease Diseases 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 229920001710 Polyorthoester Polymers 0.000 claims 2
- 210000001927 Retinal Artery Anatomy 0.000 claims 2
- 206010038897 Retinal tear Diseases 0.000 claims 2
- WYTGDNHDOZPMIW-UHOFOFEASA-O Serpentine Natural products O=C(OC)C=1[C@@H]2[C@@H]([C@@H](C)OC=1)C[n+]1c(c3[nH]c4c(c3cc1)cccc4)C2 WYTGDNHDOZPMIW-UHOFOFEASA-O 0.000 claims 2
- 208000006379 Syphilis Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 229960005188 collagen Drugs 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 201000006321 fundus dystrophy Diseases 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 201000002563 histoplasmosis Diseases 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 230000001575 pathological Effects 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- -1 poly (phosphate ester Chemical class 0.000 claims 2
- 239000002745 poly(ortho ester) Substances 0.000 claims 2
- 229920000728 polyester Polymers 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 2
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 201000005485 toxoplasmosis Diseases 0.000 claims 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 102100011470 ABCA4 Human genes 0.000 claims 1
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 210000002159 Anterior Chamber Anatomy 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 102100007149 BEST1 Human genes 0.000 claims 1
- 101700047202 BEST1 Proteins 0.000 claims 1
- 208000009137 Behcet Syndrome Diseases 0.000 claims 1
- 201000008335 Behcet's disease Diseases 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 208000003569 Central Serous Chorioretinopathy Diseases 0.000 claims 1
- 208000002765 Choroid Disease Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010070957 Choroidal haemangioma Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 201000002754 Coats disease Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 208000001763 Cytomegalovirus Retinitis Diseases 0.000 claims 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000009190 Disseminated Intravascular Coagulation Diseases 0.000 claims 1
- 208000002646 Eales disease Diseases 0.000 claims 1
- 206010014801 Endophthalmitis Diseases 0.000 claims 1
- 208000001351 Epiretinal Membrane Diseases 0.000 claims 1
- 208000000336 Familial Exudative Vitreoretinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 206010061205 Hereditary disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- 206010025169 Lyme disease Diseases 0.000 claims 1
- 206010071392 Macular fibrosis Diseases 0.000 claims 1
- 206010051058 Macular hole Diseases 0.000 claims 1
- 108010008148 Member 4 Subfamily A ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- IFVGFQAONSKBCR-UHFFFAOYSA-N N-[bis(aziridin-1-yl)phosphoryl]pyrimidin-2-amine Chemical compound C1CN1P(N1CC1)(=O)NC1=NC=CC=N1 IFVGFQAONSKBCR-UHFFFAOYSA-N 0.000 claims 1
- 206010064997 Necrotising retinitis Diseases 0.000 claims 1
- 208000001140 Night Blindness Diseases 0.000 claims 1
- 208000008940 Ocular Tuberculosis Diseases 0.000 claims 1
- 206010065700 Ocular sarcoidosis Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000008798 Osteoma Diseases 0.000 claims 1
- 208000001297 Phlebitis Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 210000001525 Retina Anatomy 0.000 claims 1
- 208000005558 Retinal Dystrophy Diseases 0.000 claims 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
- 206010038857 Retinal dystrophy Diseases 0.000 claims 1
- 206010038915 Retinitis viral Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 241000519995 Stachys sylvatica Species 0.000 claims 1
- 206010062766 Stargardt's disease Diseases 0.000 claims 1
- 206010062958 Subretinal fibrosis Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 206010044269 Toxocariasis Diseases 0.000 claims 1
- 210000001745 Uvea Anatomy 0.000 claims 1
- 208000000198 Uveal Disease Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047680 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000005845 branch retinal artery occlusion Diseases 0.000 claims 1
- 201000005849 central retinal artery occlusion Diseases 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 201000008615 cone dystrophy Diseases 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 1
- 230000003176 fibrotic Effects 0.000 claims 1
- 230000002538 fungal Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000001631 hypertensive Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 201000002165 neuroretinitis Diseases 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 201000004849 posterior scleritis Diseases 0.000 claims 1
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 1
- 230000000750 progressive Effects 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 201000007527 retinal artery occlusion Diseases 0.000 claims 1
- 201000007737 retinal degeneration Diseases 0.000 claims 1
- 239000000790 retinal pigment Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000001052 transient Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
Claims (36)
- グルココルチコイド誘導体(GD)が眼の後房に投与されるときに、生物学的に有意な量のGDの前房への拡散を防ぐのに有効な構造を有する治療的有効量のGDを含有する、眼用組成物。
- GDが2.53より大きい親油性を有する、請求項1記載の組成物。
- GDが3.5より大きい親油性を有する、請求項1記載の組成物。
- GDが4.0より大きい親油性を有する、請求項1記載の組成物。
- GDが4.2より大きい親油性を有する、請求項1記載の組成物。
- GDが10 mg/ml未満の水溶解度を有する、請求項1記載の組成物。
- GDが5 mg/ml未満の水溶解度を有する、請求項1記載の組成物。
- GDが2 mg/ml未満の水溶解度を有する、請求項1記載の組成物。
- GDが1 mg/ml未満の水溶解度を有する、請求項1記載の組成物。
- GDが0.5 mg/ml未満の水溶解度を有する、請求項1記載の組成物。
- GDが0.2 mg/ml未満の水溶解度を有する、請求項1記載の組成物。
- GDが0.14 mg/ml未満の水溶解度を有する、請求項1記載の組成物。
- GDがエステル結合によりC17に結合しているアシル基を含む、請求項1記載の組成物。
- アシル基がアセチル、ブチリル、バレリル、プロピオニル、フロイルおよびベンゾイル基からなる群から選択される、請求項13記載の組成物。
- GDがエステル結合によりC21に結合しているアシル基を含む、請求項1記載の組成物。
- アシル基がアセチル、ブチリル、バレリル、プロピオニル、フロイルおよびベンゾイル基からなる群から選択される、請求項15記載の組成物。
- GDがエステル結合によりC17およびC21の両方に結合しているアシル基を含む、請求項1記載の組成物。
- 組成物が硝子体内投与および眼周囲投与の少なくとも一つによる患者への投与に適している、請求項1記載の組成物。
- 組成物が硝子体内投与および眼周囲投与の少なくとも一つによる患者への投与に適している形態であり、ポリマー成分をさらに含む、請求項18記載の組成物。
- ポリマー成分が粘性誘発成分を含む、請求項19記載の組成物。
- ポリマー成分がヒアルロン酸を含む、請求項20記載の組成物。
- 治療成分が固体形態のGDを含有する粒子を含む、請求項1記載の組成物。
- 治療成分が固体形態のGDを含有する粒子を含む、請求項20記載の組成物。
- ポリマー成分が治療成分を含むインプラントに含まれる、請求項19記載の組成物。
- ポリマー成分が生分解性ポリマーを含む、請求項24記載の組成物。
- ポリマー成分がポリ(ラクチド-co-グリコリド)ポリマー(PLGA)、ポリ乳酸(PLA)、ポリグリコール酸(PGA)、ポリエステル、ポリ(オルトエステル)、ポリ(ホスファジン)、ポリ(リン酸エステル)、ポリカプロラクトン、ゼラチンおよびコラーゲン、およびその誘導体および組合せからなる群から選択される、請求項25記載の組成物。
- 黄斑浮腫、萎縮型および滲出型黄斑変性症、脈絡膜血管新生、糖尿病性網膜症、急性黄斑視神経網膜症、中心性漿液性網脈絡膜症、類嚢胞黄斑浮腫、糖尿病性黄斑浮腫、ブドウ膜炎、網膜炎、脈絡膜炎、急性多発性小板状色素上皮症、ベーチェット病、散弾網膜脈絡膜症、梅毒、ライム病、結核、トキソプラズマ症、中間部ブドウ膜炎(扁平部炎)、多発性脈絡膜炎、多発一過性白点症候群(mewds)、眼サルコイドーシス、後部強膜炎、蛇行性脈絡膜炎、網膜下線維症およびブドウ膜炎症候群、フォークト・小柳・原田症候群;網膜動脈閉塞性疾患、前部ブドウ膜炎、網膜静脈閉塞症、網膜中心静脈閉塞症、播種性血管内凝固障害、網膜静脈分枝閉塞症、高血圧性眼底変化、虚血性眼症候群、網膜動脈毛細血管瘤、コーツ病、傍中心窩毛細血管拡張症、片網膜静脈閉塞症、乳頭静脈炎、網膜中心動脈閉塞、網膜動脈分枝閉塞症、頸動脈疾患(CAD)、糖衣状分枝血管炎、鎌状赤血球網膜症、網膜色素線条、家族性滲出性硝子体網膜症およびイールズ病;交感性眼炎、ブドウ膜網膜疾患、網膜剥離、外傷、光凝固術、術中の潅流低下、放射線網膜症および骨髄移植網膜症などの外傷性/外科的病態;増殖性硝子体網膜症および網膜上膜、および増殖性糖尿病性網膜症;眼ヒストプラスマ症、眼内トキソカラ症、推定眼ヒストプラスマ症症候群(POHS)、眼内炎、トキソプラズマ症、HIV感染と関連する網膜疾患、HIV感染と関連する脈絡膜疾患、HIV感染と関連するブドウ膜の疾患、ウイルス性網膜炎、急性網膜壊死、進行性外側部網膜壊死、真菌性網膜疾患、眼梅毒、眼結核、広範型片側性亜急性神経網膜炎、およびハエウジ症などの感染症;網膜色素変性症、網膜ジストロフィーを伴う全身性障害、先天性停在性夜盲症、錐体ジストロフィー、スタルガルト病および黄色班眼底、ベスト病、網膜色素上皮のパターンジストロフィー、X連鎖性網膜分離症、ソルスビー眼底ジストロフィー、良性集中的黄斑変性、ビエッティ結晶ジストロフィー、および弾性線維性仮性黄色腫などの遺伝性障害;網膜剥離、黄斑円孔、および巨大網膜裂孔などの網膜裂傷/網膜裂孔;腫瘍を伴う網膜疾患、網膜色素上皮の先天性肥大、後部ブドウ膜メラノーマ、脈絡膜血管腫、脈絡膜骨腫、脈絡膜転移、網膜および網膜色素上皮の混合型過誤腫、網膜芽腫、眼底の血管増殖性腫瘍、網膜星状細胞腫、および眼内リンパ系腫瘍などの腫瘍;点状脈絡膜内層症、急性後部多発性小板状色素上皮症、近視性網膜変性、急性網膜色素上皮炎、網膜色素変性症、増殖性硝子体網膜症(PVR)、加齢性黄斑変性症(ARMD)、糖尿病性網膜症、糖尿病性黄斑浮腫、網膜剥離、網膜裂傷、ブドウ膜炎、サイトメガロウイルス性網膜炎および緑内障からなる群から選択される哺乳動物の眼の後区の病態の治療用キットであって、GDを眼科的に有効なビヒクル中にて含む組成物をその眼の後区に投与することを含む、キット。
- 組成物が硝子体内投与される、請求項27記載のキット。
- 組成物がGD粒子の懸濁物を含む、請求項28記載のキット。
- 組成物がポリマー成分を含む、請求項29記載のキット。
- ポリマー成分がヒアルロン酸を含む、請求項30記載のキット。
- 病態が黄斑浮腫を含む、請求項31記載のキット。
- 病態が黄斑変性症を含む、請求項32記載のキット。
- 組成物がGDおよび生体適合性ポリマーを含む硝子体内インプラントを含む、請求項28記載のキット。
- ポリマーが生分解性ポリマーである、請求項32記載のキット。
- 生分解性ポリマーがポリ(ラクチド-co-グリコリド)ポリマー(PLGA)、ポリ乳酸(PLA)、ポリグリコール酸(PGA)、ポリエステル、ポリ(オルトエステル)、ポリ(ホスファジン)、ポリ(リン酸エステル)、ポリカプロラクトン、ゼラチンおよびコラーゲンならびにその誘導体および組合せからなる群から選択される、請求項35記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72820905P | 2005-10-18 | 2005-10-18 | |
US60/728,209 | 2005-10-18 | ||
PCT/US2006/040429 WO2007047607A2 (en) | 2005-10-18 | 2006-10-17 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013213746A Division JP2014028855A (ja) | 2005-10-18 | 2013-10-11 | 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009511632A JP2009511632A (ja) | 2009-03-19 |
JP2009511632A5 true JP2009511632A5 (ja) | 2009-11-12 |
JP5745208B2 JP5745208B2 (ja) | 2015-07-08 |
Family
ID=37872252
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008536724A Active JP5745208B2 (ja) | 2005-10-18 | 2006-10-17 | 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療 |
JP2013213746A Withdrawn JP2014028855A (ja) | 2005-10-18 | 2013-10-11 | 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013213746A Withdrawn JP2014028855A (ja) | 2005-10-18 | 2013-10-11 | 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療 |
Country Status (11)
Country | Link |
---|---|
US (5) | US8062657B2 (ja) |
EP (1) | EP1937210B1 (ja) |
JP (2) | JP5745208B2 (ja) |
KR (1) | KR101430760B1 (ja) |
CN (1) | CN101394834A (ja) |
AU (1) | AU2006304416B2 (ja) |
BR (1) | BRPI0613401B8 (ja) |
CA (1) | CA2602577C (ja) |
MX (2) | MX339797B (ja) |
NZ (1) | NZ562032A (ja) |
WO (1) | WO2007047607A2 (ja) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
US20080220049A1 (en) * | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
MX339797B (es) * | 2005-10-18 | 2016-06-10 | Allergan Inc | Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior. |
US20090082321A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
EP2727936B1 (en) | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
HUE055815T2 (hu) * | 2007-10-05 | 2021-12-28 | Univ Wayne State | Vegyületek nyújtott felszabadítására alkalmas dendrimerek |
US8353862B2 (en) | 2007-11-02 | 2013-01-15 | Allergan, Inc. | Drug delivery systems and methods |
WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
JP2013515741A (ja) * | 2009-12-23 | 2013-05-09 | サイヴィーダ ユーエス,インコーポレイテッド | 持続放出性送達デバイス |
CN103180339B (zh) | 2010-05-26 | 2016-04-27 | 百时美施贵宝公司 | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 |
US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
US10463687B2 (en) * | 2011-01-20 | 2019-11-05 | Cornell University | Treatments for retinal disorders |
US10501779B2 (en) * | 2011-05-12 | 2019-12-10 | President And Fellows Of Harvard College | Oligonucleotide trapping |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
EP2847207B1 (en) | 2012-05-08 | 2019-03-27 | Nicox Ophthalmics, Inc. | Fluticasone propionate nanocrystals |
US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
JP6302091B2 (ja) | 2014-04-30 | 2018-03-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | デンドリマー組成物および眼の疾患の処置におけるその使用 |
JP6655610B2 (ja) | 2014-05-29 | 2020-02-26 | グローコス コーポレーション | 制御された薬物送達機能を備えるインプラント及びそれを使用する方法 |
JP6342575B2 (ja) | 2014-08-13 | 2018-06-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 脳腫瘍への選択的デンドリマー送達 |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
EP3360066A1 (en) * | 2015-10-07 | 2018-08-15 | Genentech, Inc. | Systems and methods for predicting vitreal half-life of therapeutic agent-polymer conjugates |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
CN106983733A (zh) * | 2017-03-08 | 2017-07-28 | 江苏富泽药业有限公司 | 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用 |
EP3675895B1 (en) * | 2017-09-01 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Compositions for treating macular edema |
WO2019055028A1 (en) * | 2017-09-15 | 2019-03-21 | Kala Pharmaceuticals, Inc. | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS |
AU2020396561A1 (en) | 2019-12-04 | 2022-07-14 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to the eye |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
EP0244178A3 (en) | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
ES2078175B1 (es) | 1993-12-31 | 1996-10-16 | Cusi Lab | Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones. |
US5646136A (en) | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
NZ336035A (en) | 1996-11-05 | 2002-03-28 | Childrens Medical Center | Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug |
DE69827138T2 (de) | 1997-08-11 | 2006-02-23 | Allergan, Inc., Irvine | Steriles Retinoid enthaltendes biodegradierbares Implantat mit verbesserter Biokompatibilität und Verfahren zu dessen Herstellung |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
AUPQ496500A0 (en) | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
ATE306951T1 (de) * | 2000-11-29 | 2005-11-15 | Allergan Inc | Verhinderung von transplantatabstossung im auge |
US20030185892A1 (en) | 2001-08-17 | 2003-10-02 | Bell Steve J. D. | Intraocular delivery compositions and methods |
US6933340B2 (en) | 2001-12-12 | 2005-08-23 | Rhodia Chimie | Formulation comprising an ionic compound, a polyionic polymer, and a block copolymer |
US6873524B2 (en) * | 2002-08-15 | 2005-03-29 | Audavi Corporation | Data storage device |
US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
JP2006518382A (ja) * | 2003-02-20 | 2006-08-10 | アルコン,インコーポレイテッド | 眼の障害に罹患している人を処置するためのステロイドの使用 |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
AU2005209201B2 (en) * | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
MX339797B (es) | 2005-10-18 | 2016-06-10 | Allergan Inc | Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior. |
JP2007309763A (ja) | 2006-05-18 | 2007-11-29 | Sumitomo Electric Ind Ltd | 電線の表面欠陥検出装置 |
-
2006
- 2006-10-17 MX MX2012007846A patent/MX339797B/es unknown
- 2006-10-17 WO PCT/US2006/040429 patent/WO2007047607A2/en active Application Filing
- 2006-10-17 KR KR1020077028609A patent/KR101430760B1/ko active IP Right Grant
- 2006-10-17 CA CA2602577A patent/CA2602577C/en active Active
- 2006-10-17 JP JP2008536724A patent/JP5745208B2/ja active Active
- 2006-10-17 NZ NZ562032A patent/NZ562032A/en unknown
- 2006-10-17 AU AU2006304416A patent/AU2006304416B2/en active Active
- 2006-10-17 EP EP06826056.1A patent/EP1937210B1/en active Active
- 2006-10-17 MX MX2007012061A patent/MX2007012061A/es active IP Right Grant
- 2006-10-17 CN CNA2006800164791A patent/CN101394834A/zh active Pending
- 2006-10-17 BR BRPI0613401A patent/BRPI0613401B8/pt active IP Right Grant
- 2006-10-18 US US11/550,642 patent/US8062657B2/en active Active
-
2011
- 2011-11-17 US US13/299,215 patent/US8840872B2/en active Active
-
2013
- 2013-10-11 JP JP2013213746A patent/JP2014028855A/ja not_active Withdrawn
-
2014
- 2014-08-19 US US14/463,034 patent/US9259429B2/en active Active
-
2016
- 2016-02-15 US US15/043,750 patent/US9820995B2/en active Active
-
2017
- 2017-11-20 US US15/818,089 patent/US10188665B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009511632A5 (ja) | ||
JP6132964B2 (ja) | 萎縮性加齢性黄斑変性の処置方法 | |
AU2018211329A1 (en) | Intraocular sustained release drug delivery systems and methods for treating ocular conditions | |
JP5484911B2 (ja) | 眼内使用のための環状脂質インプラントの製造法 | |
ES2658175T3 (es) | Implantes intracamerales de agentes terapéuticos de liberación sostenida | |
US10959954B2 (en) | Dexamethasone prodrug compositions and uses thereof | |
JP2008505978A (ja) | 眼病用組成物および眼病治療法 | |
JP2007535552A5 (ja) | ||
JP2007535367A (ja) | エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法 | |
JP2018503736A (ja) | 眼内圧を抑える抗緑内障剤の持続放出のための組成物 | |
KR20210009315A (ko) | 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물 | |
US20220089635A1 (en) | Crystalline forms of dexamethasone dimers and uses thereof | |
CA2598095A1 (en) | Method of relieving or avoiding side effect of steroid | |
WO2021237096A1 (en) | Durable implants and microparticles for long-term ocular therapy | |
US20110257186A1 (en) | Compositions and methods for treating visual disorders | |
JP2013501794A (ja) | 目の疾患を治療するためのイソチオゾール |